Capstone Investment Advisors LLC Lowers Position in Geron Co. (NASDAQ:GERN)

Capstone Investment Advisors LLC decreased its stake in Geron Co. (NASDAQ:GERNFree Report) by 47.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,437 shares of the biopharmaceutical company’s stock after selling 56,192 shares during the quarter. Capstone Investment Advisors LLC’s holdings in Geron were worth $134,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in GERN. RA Capital Management L.P. increased its holdings in Geron by 46.5% in the 3rd quarter. RA Capital Management L.P. now owns 46,202,425 shares of the biopharmaceutical company’s stock worth $97,949,000 after acquiring an additional 14,657,619 shares in the last quarter. Vivo Capital LLC raised its position in shares of Geron by 46.1% during the 4th quarter. Vivo Capital LLC now owns 24,143,681 shares of the biopharmaceutical company’s stock valued at $50,943,000 after purchasing an additional 7,619,047 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Geron by 172.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,634,330 shares of the biopharmaceutical company’s stock valued at $7,705,000 after buying an additional 2,300,220 shares in the last quarter. MPM Bioimpact LLC boosted its holdings in Geron by 16.6% in the 3rd quarter. MPM Bioimpact LLC now owns 10,712,481 shares of the biopharmaceutical company’s stock worth $22,710,000 after buying an additional 1,521,191 shares during the period. Finally, Walleye Capital LLC increased its stake in Geron by 146.5% in the 3rd quarter. Walleye Capital LLC now owns 2,226,066 shares of the biopharmaceutical company’s stock worth $4,719,000 after buying an additional 1,322,938 shares in the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Stock Up 4.2 %

GERN stock opened at $3.99 on Wednesday. The firm has a fifty day moving average price of $3.61 and a 200 day moving average price of $2.65. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.67 and a quick ratio of 3.67. Geron Co. has a fifty-two week low of $1.64 and a fifty-two week high of $4.30.

Geron (NASDAQ:GERNGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.15 million. Geron had a negative net margin of 38,730.00% and a negative return on equity of 68.16%. Sell-side analysts forecast that Geron Co. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Geron in a research note on Wednesday, April 10th. Robert W. Baird downgraded Geron from an “outperform” rating to a “neutral” rating and set a $4.50 price target for the company. in a research note on Tuesday, April 30th. TD Cowen assumed coverage on shares of Geron in a research report on Monday, April 29th. They set a “buy” rating and a $10.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and issued a $5.00 target price on shares of Geron in a report on Thursday, May 2nd. Finally, The Goldman Sachs Group raised their target price on shares of Geron from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Friday, March 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.10.

Get Our Latest Report on GERN

Geron Company Profile

(Free Report)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Featured Stories

Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERNFree Report).

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.